Sabine Kasimir-Bauer Selected Research

Circulating Neoplastic Cells

4/2022	Programmed death receptor ligand-2 (PD-L2) bearing extracellular vesicles as a new biomarker to identify early triple-negative breast cancer patients at high risk for relapse.
3/2022	Combinatorial Power of cfDNA, CTCs and EVs in Oncology.
1/2021	Integrative statistical analyses of multiple liquid biopsy analytes in metastatic breast cancer.
1/2021	Longitudinal Multi-Parametric Liquid Biopsy Approach Identifies Unique Features of Circulating Tumor Cell, Extracellular Vesicle, and Cell-Free DNA Characterization for Disease Monitoring in Metastatic Breast Cancer Patients.
10/2020	Liquid Biopsies to Evaluate Immunogenicity of Gynecological/Breast Tumors: On the Way to Blood-Based Biomarkers for Immunotherapies.
4/2020	Multimodal Targeted Deep Sequencing of Circulating Tumor Cells and Matched Cell-Free DNA Provides a More Comprehensive Tool to Identify Therapeutic Targets in Metastatic Breast Cancer Patients.
1/2020	Circulating Tumor Cells Expressing the Prostate Specific Membrane Antigen (PSMA) Indicate Worse Outcome in Primary, Non-Metastatic Triple-Negative Breast Cancer.
2/2019	Cell-Free DNA Variant Sequencing Using CTC-Depleted Blood for Comprehensive Liquid Biopsy Testing in Metastatic Breast Cancer.
1/2019	HLA-G 3' untranslated region variants +3187G/G, +3196G/G and +3035T define diametrical clinical status and disease outcome in epithelial ovarian cancer.
1/2019	The prognostic relevance of urokinase-type plasminogen activator (uPA) in the blood of patients with metastatic breast cancer.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Sabine Kasimir-Bauer Research Topics

Disease

66	Neoplasms (Cancer) 05/2022 - 12/2003
41	Breast Neoplasms (Breast Cancer) 05/2022 - 12/2003
31	Circulating Neoplastic Cells 04/2022 - 06/2009
28	Ovarian Neoplasms (Ovarian Cancer) 12/2021 - 04/2005
13	Disease Progression 04/2022 - 01/2010
13	Neoplasm Metastasis (Metastasis) 01/2019 - 03/2003
11	Ovarian Epithelial Carcinoma 09/2020 - 03/2009
11	Residual Neoplasm 08/2019 - 07/2009
3	Triple Negative Breast Neoplasms 04/2022 - 01/2020
3	Carcinogenesis 01/2019 - 03/2009
3	Pre-Eclampsia (Preeclampsia) 11/2015 - 01/2007
2	Neoplasm Micrometastasis 04/2020 - 01/2009
2	Carcinoma (Carcinomatosis) 01/2019 - 01/2012
2	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 06/2011 - 03/2003
1	Microsatellite Instability 10/2020
1	Prostatic Neoplasms (Prostate Cancer) 01/2020
1	Pathologic Complete Response 02/2016
1	Rupture 01/2016
1	Preterm Premature Rupture of the Membranes 01/2016
1	Obesity 09/2014
1	Glucose Intolerance 09/2014
1	Insulin Resistance 09/2014
1	Inflammation (Inflammations) 09/2014

Drug/Important Bio-Agent (IBA)

29	Biomarkers (Surrogate Marker)IBA 04/2022 - 07/2009
16	PlatinumIBA 12/2021 - 11/2007
11	Cell-Free Nucleic AcidsIBA 03/2022 - 01/2011
11	DNA (Deoxyribonucleic Acid)IBA 12/2021 - 01/2009
11	Epithelial Cell Adhesion MoleculeIBA 07/2017 - 12/2003
10	Hormones (Hormone)IBA 08/2021 - 08/2011
8	AntigensIBA 05/2022 - 12/2003
6	Proteins (Proteins, Gene)FDA Link 09/2020 - 11/2002
6	Circulating Tumor DNAIBA 01/2019 - 01/2009
6	Keratins (Keratin)IBA 10/2011 - 03/2003
5	Messenger RNA (mRNA)IBA 01/2021 - 01/2018
5	MicroRNAs (MicroRNA)IBA 01/2019 - 06/2011
5	Estrogen ReceptorsIBA 01/2018 - 01/2009
4	human ERBB2 proteinIBA 01/2021 - 12/2017
4	HLA-G Antigens (HLA G)IBA 01/2021 - 09/2016
4	LigandsIBA 10/2020 - 01/2019
4	ErbB Receptors (EGF Receptor)IBA 04/2020 - 02/2006
4	RNA (Ribonucleic Acid)IBA 01/2019 - 06/2011
4	Urokinase-Type Plasminogen Activator (Urokinase)FDA Link 01/2019 - 02/2006
4	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2019 - 01/2007
4	Tumor Biomarkers (Tumor Markers)IBA 01/2018 - 07/2013
4	Progesterone Receptors (Progesterone Receptor)IBA 01/2016 - 01/2009
3	HLA Antigens (Human Leukocyte Antigens)IBA 01/2021 - 09/2016
3	Estrogens (Estrogen)FDA Link 01/2016 - 01/2010
3	Indicators and Reagents (Reagents)IBA 01/2016 - 01/2009
3	PicoGreenIBA 06/2011 - 01/2011
3	CaspasesIBA 06/2011 - 01/2011
2	Immune Checkpoint InhibitorsIBA 04/2022 - 10/2020
2	Death Domain ReceptorsIBA 04/2022 - 01/2019
2	3' Untranslated Regions (3' UTR)IBA 01/2021 - 01/2019
2	Membrane Proteins (Integral Membrane Proteins)IBA 10/2020 - 07/2009
2	Aurora Kinase AIBA 01/2020 - 01/2018
2	ParaffinIBA 11/2019 - 07/2009
2	EnzymesIBA 01/2016 - 02/2006
2	Diphosphonates (Bisphosphonates)IBA 01/2016 - 07/2013
2	Neural Cell Adhesion Molecule L1 (L1 Cell Adhesion Molecule)IBA 01/2013 - 08/2009
2	Proteasome Endopeptidase Complex (Proteasome)IBA 06/2011 - 02/2011
2	Plasminogen Activators (Plasminogen Activator)IBA 06/2011 - 02/2006
2	Peptide Hydrolases (Proteases)FDA Link 06/2011 - 01/2011
2	Carboplatin (JM8)FDA LinkGeneric 06/2011 - 11/2007
2	Nucleosomes (Nucleosome)IBA 06/2011 - 01/2011
2	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 01/2009 - 01/2007
1	SuspensionsIBA 05/2022
1	Neuropilin-1IBA 08/2021
1	ProteomeIBA 11/2020
1	T-Cell Antigen Receptors (T-Cell Receptor)IBA 10/2020
1	PeriostinIBA 04/2020
1	Chemokine ReceptorsIBA 01/2020
1	Complementary DNA (cDNA)IBA 01/2020
1	Transcription Factors (Transcription Factor)IBA 01/2020
1	Formaldehyde (Formol)FDA Link 11/2019
1	OsteoprotegerinIBA 01/2019
1	CytokinesIBA 11/2018
1	Biological ProductsIBA 11/2018
1	GoldIBA 12/2017
1	Phosphoric Monoester Hydrolases (Phosphatases)IBA 05/2017
1	Phosphatidylinositol 3-Kinase (1 Phosphatidylinositol 3 Kinase)IBA 05/2017
1	TensinsIBA 05/2017
1	Protein Serine-Threonine Kinases (Protein-Serine-Threonine Kinase)IBA 05/2017
1	Carbohydrate Tumor-Associated Antigens (Antigens, Tumor-Associated Carbohydrate)IBA 12/2016
1	Clodronic Acid (Clodronate)IBA 01/2016
1	ImmunosorbentsIBA 01/2016
1	Progesterone FDA LinkGeneric 01/2016
1	catumaxomabIBA 12/2015
1	Natriuretic PeptidesIBA 11/2015
1	ProcalcitoninIBA 11/2015
1	Glucose (Dextrose)FDA LinkGeneric 09/2014

Therapy/Procedure

29	Therapeutics 05/2022 - 11/2002
18	Drug Therapy (Chemotherapy) 04/2022 - 11/2002
6	Neoadjuvant Therapy 01/2021 - 02/2016
3	Immunotherapy 10/2020 - 12/2003
2	Palliative Care (Palliative Therapy) 07/2016 - 08/2011
1	Precision Medicine 01/2019
1	Lasers (Laser) 12/2017
1	Adjuvant Chemotherapy 07/2017
1	Aftercare (After-Treatment) 02/2016
1	Radiotherapy 01/2016